Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland
Open Access
- 12 November 2025
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 13 (22) , 2874
Abstract
Background: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration. Aim: The aim of the study was to assess the clinical characteristics of patients treated with GLP-1 RA in Poland in 2018–2024, with particular emphasis on the disease entities constituting indications for treatment (like obesity and diabetes), and to analyse the frequency of use of individual drugs during the study period. Methods: A cohort study was conducted based on anonymised medical data from 300 outpatient clinics the largest private healthcare facilities in Poland (Luxmed), on consecutive patients who had at least one prescription for GLP-1 RA. The analysis covered the period from 1 January 2018 to 31 December 2024. Results: The number of patients using GLP-1 RA increased from 212 in 2018 to 12,836 in 2024. Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%). From 2022, the share of oral semaglutide steadily increased, reaching 50% of all semaglutide applications in 2024 in Poland. Conclusions: In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history.Keywords
This publication has 19 references indexed in Scilit:
- Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)Advances in Therapy, 2025
- GLP ‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?The Laryngoscope, 2025
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityNew England Journal of Medicine, 2025
- 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular HealthJACC, 2025
- KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to knowAmerican Journal of Health-System Pharmacy, 2025
- GLP-1RA Use and Thyroid Cancer RiskJAMA Otolaryngology–Head & Neck Surgery, 2025
- Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort StudyThyroid®, 2025
- Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022Journal of the American Pharmacists Association, 2023
- Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)European Journal of Clinical Pharmacology, 2023
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022